Nicole L Michmerhuizen1, Elizabeth Leonard2, Aditi Kulkarni2, J Chad Brenner3. 1. Department of Otolaryngology - Head and Neck Surgery, University of Michigan Medical School, Ann Arbor, MI.; Department of Pharmacology, University of Michigan Medical School, Ann Arbor, MI. 2. Department of Otolaryngology - Head and Neck Surgery, University of Michigan Medical School, Ann Arbor, MI. 3. Department of Otolaryngology - Head and Neck Surgery, University of Michigan Medical School, Ann Arbor, MI.; Cellular and Molecular Biology Program, University of Michigan, Ann Arbor, MI; Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI.
Abstract
OBJECTIVE: Recent sequencing studies of head and neck squamous cell carcinomas (HNSCCs) have identified the phosphatidylinositol 3-kinase (PI3K) pathway as the most frequently mutated, oncogenic pathway in this cancer type. Despite the frequency of activating genomic alterations in PIK3CA (the gene encoding the catalytic subunit of PI3K, targeted inhibitors of PI3K have not shown clinical efficacy as monotherapies. We hypothesized that co-dependent pathways, including the Ras-MEK-ERK pathway, may still be functional in the presence of PI3K inhibitors and might serve as mediators of this resistance. METHODS: We assessed the hypothesis using resazurin cell viability and trypan blue exclusion assays. We also used Western blot to characterize Ras-MEK-ERK pathway activity. STUDY DESIGN: We evaluated this hypothesis in six PIK3CA-amplified, PI3K inhibitor-resistant HNSCC cell lines following treatment with pan and alpha-isoform selective PI3K inhibitors (BKM120 and HS-173 respectively). We also tested the effect of combination treatment with PI3K inhibitor HS-173 and MEK inhibitor trametinib or EGFR inhibitor gefitinib. RESULTS: Our results displayed maintenance of Ras-MEK-ERK pathway activity in 4 of 6 HNSCC cell lines after PI3K inhibitor treatment. We also found that UM-SCC-69 and UM-SCC-108 cells display synergistic responses to dual therapy. CONCLUSION: This study suggests that inhibition of the PI3K and Ras-MEK-ERK pathways might be effective in some HNSCC patients; however, it also prompts the study of additional resistance mechanisms to identify synergistic combination therapies for tumors resistant to these di-therapies.
OBJECTIVE: Recent sequencing studies of head and neck squamous cell carcinomas (HNSCCs) have identified the phosphatidylinositol 3-kinase (PI3K) pathway as the most frequently mutated, oncogenic pathway in this cancer type. Despite the frequency of activating genomic alterations in PIK3CA (the gene encoding the catalytic subunit of PI3K, targeted inhibitors of PI3K have not shown clinical efficacy as monotherapies. We hypothesized that co-dependent pathways, including the Ras-MEK-ERK pathway, may still be functional in the presence of PI3K inhibitors and might serve as mediators of this resistance. METHODS: We assessed the hypothesis using resazurin cell viability and trypan blue exclusion assays. We also used Western blot to characterize Ras-MEK-ERK pathway activity. STUDY DESIGN: We evaluated this hypothesis in six PIK3CA-amplified, PI3K inhibitor-resistant HNSCC cell lines following treatment with pan and alpha-isoform selective PI3K inhibitors (BKM120 and HS-173 respectively). We also tested the effect of combination treatment with PI3K inhibitor HS-173 and MEK inhibitor trametinib or EGFR inhibitor gefitinib. RESULTS: Our results displayed maintenance of Ras-MEK-ERK pathway activity in 4 of 6 HNSCC cell lines after PI3K inhibitor treatment. We also found that UM-SCC-69 and UM-SCC-108 cells display synergistic responses to dual therapy. CONCLUSION: This study suggests that inhibition of the PI3K and Ras-MEK-ERK pathways might be effective in some HNSCC patients; however, it also prompts the study of additional resistance mechanisms to identify synergistic combination therapies for tumors resistant to these di-therapies.
Entities:
Keywords:
Compensatory Resistance; Head and Neck Cancer; PIK3CA; Personalized Medicine; Targeted Therapy
Authors: Suresh Mohan; Robert Vander Broek; Sujay Shah; Danielle F Eytan; Matthew L Pierce; Sophie G Carlson; Jamie F Coupar; Jialing Zhang; Hui Cheng; Zhong Chen; Carter Van Waes Journal: Clin Cancer Res Date: 2015-05-14 Impact factor: 12.531
Authors: Filip Janku; David S Hong; Siqing Fu; Sarina A Piha-Paul; Aung Naing; Gerald S Falchook; Apostolia M Tsimberidou; Vanda M Stepanek; Stacy L Moulder; J Jack Lee; Rajyalakshmi Luthra; Ralph G Zinner; Russell R Broaddus; Jennifer J Wheler; Razelle Kurzrock Journal: Cell Rep Date: 2014-01-16 Impact factor: 9.423
Authors: Antonio Jimeno; Julie E Bauman; Charles Weissman; Douglas Adkins; Ian Schnadig; Patrice Beauregard; Daniel W Bowles; Alexander Spira; Benjamin Levy; Nagashree Seetharamu; Diana Hausman; Luke Walker; Charles M Rudin; Keisuke Shirai Journal: Oral Oncol Date: 2015-01-13 Impact factor: 5.337
Authors: Annett Mueller; Erika Bachmann; Monika Linnig; Katrin Khillimberger; Carl Christoph Schimanski; Peter R Galle; Markus Moehler Journal: Cancer Chemother Pharmacol Date: 2012-04-29 Impact factor: 3.333
Authors: Vivian W Y Lui; Matthew L Hedberg; Hua Li; Bhavana S Vangara; Kelsey Pendleton; Yan Zeng; Yiling Lu; Qiuhong Zhang; Yu Du; Breean R Gilbert; Maria Freilino; Sam Sauerwein; Noah D Peyser; Dong Xiao; Brenda Diergaarde; Lin Wang; Simion Chiosea; Raja Seethala; Jonas T Johnson; Seungwon Kim; Umamaheswar Duvvuri; Robert L Ferris; Marjorie Romkes; Tomoko Nukui; Patrick Kwok-Shing Ng; Levi A Garraway; Peter S Hammerman; Gordon B Mills; Jennifer R Grandis Journal: Cancer Discov Date: 2013-04-25 Impact factor: 39.397
Authors: J Chad Brenner; Martin P Graham; Bhavna Kumar; Lindsay M Saunders; Robbi Kupfer; Robert H Lyons; Carol R Bradford; Thomas E Carey Journal: Head Neck Date: 2010-04 Impact factor: 3.147
Authors: Megan L Ludwig; Andrew C Birkeland; Rebecca Hoesli; Paul Swiecicki; Matthew E Spector; J Chad Brenner Journal: Cancer Biol Med Date: 2016-03 Impact factor: 4.248
Authors: M R Yun; H M Choi; H N Kang; Yw Lee; H-S Joo; D H Kim; H R Kim; M H Hong; S O Yoon; B C Cho Journal: Oncogene Date: 2017-09-25 Impact factor: 9.867
Authors: Megan L Ludwig; Aditi Kulkarni; Andrew C Birkeland; Nicole L Michmerhuizen; Susan K Foltin; Jacqueline E Mann; Rebecca C Hoesli; Samantha N Devenport; Brittany M Jewell; Andrew G Shuman; Matthew E Spector; Thomas E Carey; Hui Jiang; J Chad Brenner Journal: Oral Oncol Date: 2018-11-08 Impact factor: 5.337
Authors: George D Wilson; Thomas G Wilson; Alaa Hanna; Mohamad Dabjan; Katie Buelow; John Torma; Brian Marples; Sandra Galoforo Journal: Clin Transl Radiat Oncol Date: 2020-11-08
Authors: Nicole L Michmerhuizen; Megan L Ludwig; Andrew C Birkeland; Sai Nimmagadda; Jingyi Zhai; Jiayu Wang; Brittany M Jewell; Dylan Genouw; Lindsay Remer; Daniel Kim; Susan K Foltin; Apurva Bhangale; Aditi Kulkarni; Carol R Bradford; Paul L Swiecicki; Thomas E Carey; Hui Jiang; J Chad Brenner Journal: Head Neck Date: 2022-02-27 Impact factor: 3.821
Authors: Daniela Cochicho; Susana Esteves; Miguel Rito; Fernanda Silva; Luís Martins; Pedro Montalvão; Mário Cunha; Miguel Magalhães; Rui M Gil da Costa; Ana Felix Journal: Cancers (Basel) Date: 2022-03-02 Impact factor: 6.639